Table 1.
Correlations of sirtuins and clinicopathological parameters in patients with NSCLC
| Parameters | N | SIRT1
|
SIRT2
|
SIRT3
|
SIRT4
|
SIRT5
|
SIRT6
|
SIRT7
|
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Low | High | P-value | Low | High | P-value | Low | High | P-value | Low | High | P-value | Low | High | P-value | Low | High | P-value | Low | High | P-value | ||
| Histology | ||||||||||||||||||||||
| ADC | 515 | 109 (21.17%) |
406 (78.83%) |
0.000 | 237 (46.02%) |
278 (53.98%) |
0.000 | 293 (56.89%) |
222 (43.11%) |
0.000 | 308 (59.81%) |
207 (40.19%) |
0.000 | 331 (64.27%) |
184 (35.73%) |
0.000 | 361 (70.1%) |
154 (29.9%) |
0.788 | 202 (39.22%) |
313 (60.78%) |
0.046 |
| SCC | 502 | 313 (62.35%) |
189 (37.65%) |
127 (25.30%) |
375 (74.70%) |
417 (83.07%) |
85 (16.93%) |
445 (88.65%) |
57 (11.35%) |
196 (39.04%) |
306 (60.96%) |
348 (69.32%) |
154 (30.68%) |
228 (45.42%) |
274 (54.58%) |
|||||||
| Gender | ||||||||||||||||||||||
| Female | 402 | 133 (33.08%) |
269 (66.92%) |
0.000 | 138 (34.33%) |
264 (65.67%) |
0.409 | 258 (64.18%) |
144 (35.82%) |
0.001 | 272 (67.66%) |
130 (32.34%) |
0.000 | 243 (60.45%) |
159 (39.55%) |
0.000 | 280 (69.65%) |
122 (30.35%) |
0.924 | 170 (42.29%) |
232 (57.71%) |
0.976 |
| Male | 602 | 280 (46.51%) |
322 (53.49%) |
222 (36.88%) |
380 (63.12%) |
445 (73.92%) |
157 (26.08%) |
472 (78.41%) |
130 (21.59%) |
280 (46.51%) |
322 (53.49%) |
421 (69.93%) |
181 (30.07%) |
254 (42.19%) |
348 (57.81%) |
|||||||
| Age | ||||||||||||||||||||||
| <70 years | 627 | 258 (41.15%) |
369 (58.85%) |
0.999 | 234 (37.32%) |
393 (62.68%) |
0.192 | 444 (70.81%) |
183 (29.19%) |
0.522 | 454 (72.41%) |
173 (27.59%) |
0.155 | 314 (50.08%) |
313 (49.92%) |
0.178 | 433 (69.06%) |
194 (30.94%) |
0.831 | 244 (38.92%) |
383 (61.08%) |
0.012 |
| ≥70 years | 350 | 144 (41.14%) |
206 (58.86%) |
116 (33.14%) |
234 (66.86%) |
241 (68.86%) |
109 (31.14%) |
268 (76.57%) |
82 (23.43%) |
191 (54.57%) |
159 (45.43%) |
244 (69.71%) |
106 (30.29%) |
165 (47.14%) |
185 (52.86%) |
|||||||
| M stage | ||||||||||||||||||||||
| M0 | 747 | 327 (43.78%) |
420 (56.22%) |
0.014 | 252 (33.73%) |
495 (66.27%) |
0.125 | 535 (71.62%) |
212 (28.38%) |
0.463 | 551 (73.76%) |
196 (26.24%) |
0.876 | 375 (50.20%) |
372 (49.80%) |
0.715 | 529 (70.82%) |
218 (29.18%) |
0.202 | 320 (42.84%) |
427 (57.16%) |
0.343 |
| M1 | 32 | 7 (21.88%) |
25 (78.13%) |
15 (46.88%) |
17 (53.13%) |
21 (65.63%) |
11 (34.38%) |
24 (75.00%) |
8 (25.00%) |
15 (46.88%) |
17 (53.13%) |
26 (81.25%) |
6 (18.75%) |
11 (34.38%) |
21 (65.63%) |
|||||||
| N stage | ||||||||||||||||||||||
| N0 | 642 | 258 (40.19%) |
384 (59.81%) |
0.299 | 225 (35.05%) |
417 (64.95%) |
0.444 | 452 (70.4%) |
190 (29.6%) |
0.910 | 469 (73.05%) |
173 (26.95%) |
0.142 | 326 (50.78%) |
316 (49.22%) |
0.246 | 455 (70.87%) |
187 (29.13%) |
0.353 | 273 (42.52%) |
369 (57.48%) |
0.521 |
| N1–3 | 344 | 150 (43.6%) |
194 (56.4%) |
129 (37.5%) |
215 (62.5%) |
241 (70.06%) |
103 (29.94%) |
266 (77.33%) |
78 (22.67%) |
188 (54.65%) |
156 (45.35%) |
234 (68.02%) |
110 (31.98%) |
139 (40.41%) |
205 (59.59%) |
|||||||
| T stage | ||||||||||||||||||||||
| T1 | 280 | 95 (33.93%) |
185 (66.07%) |
0.003 | 96 (34.29%) |
184 (65.71%) |
0.516 | 188 (67.14%) |
92 (32.86%) |
0.214 | 195 (69.64%) |
85 (30.36%) |
0.039 | 148 (52.86%) |
132 (47.14%) |
0.780 | 203 (72.50%) |
77 (27.50%) |
0.235 | 115 (41.07%) |
165 (58.93%) |
0.665 |
| T2–4 | 721 | 318 (44.11%) |
403 (55.89%) |
263 (36.48%) |
458 (63.52%) |
513 (71.15%) |
208 (28.85%) |
548 (76.01%) |
173 (23.99%) |
374 (51.87%) |
347 (48.13%) |
495 (68.65%) |
226 (31.35%) |
307 (42.58%) |
414 (57.42%) |
|||||||
| Stage | ||||||||||||||||||||||
| I–II | 518 | 207 (39.96%) |
311 (60.04%) |
0.448 | 174 (33.59%) |
344 (66.41%) |
0.131 | 352 (67.95%) |
166 (32.05%) |
0.143 | 368 (71.04%) |
150 (28.96%) |
0.022 | 259 (50.00%) |
259 (50.00%) |
0.131 | 373 (72.01%) |
145 (27.99%) |
0.132 | 228 (44.02%) |
290 (55.98%) |
0.228 |
| III–IV | 482 | 204 (42.32%) |
278 (57.68%) |
184 (38.17%) |
298 (61.83%) |
348 (72.2%) |
134 (27.8%) |
373 (77.39%) |
109 (22.61%) |
264 (54.77%) |
218 (45.23%) |
326 (67.63%) |
156 (32.37%) |
194 (40.25%) |
288 (59.75%) |
|||||||
| Smoking status | ||||||||||||||||||||||
| Yes | 890 | 381 (42.81%) |
509 (57.19%) |
0.001 | 314 (35.28%) |
576 (64.72%) |
0.388 | 631 (70.90%) |
259 (29.10%) |
0.054 | 672 (75.51%) |
218 (24.49%) |
0.006 | 447 (50.22%) |
443 (49.78%) |
0.009 | 624 (70.11%) |
266 (29.89%) |
0.698 | 369 (41.46%) |
521 (58.54%) |
0.059 |
| No | 93 | 23 (24.73%) |
70 (75.27%) |
37 (39.78%) |
56 (60.22%) |
57 (61.29%) |
36 (38.71%) |
58 (62.37%) |
35 (37.63%) |
60 (64.52%) |
33 (35.48%) |
67 (72.04%) |
26 (27.96%) |
48 (51.61%) |
45 (48.39%) |
|||||||
Note: Bold: P<0.05 demonstrated by chi-square test.
Abbreviations: NSCLC, non–small cell lung cancer; SIRT1, sirtuin 1; SIRT2, sirtuin 2; SIRT3, sirtuin 3; SIRT4, sirtuin 4; SIRT5, sirtuin 5; SIRT6, sirtuin 6; SIRT7, sirtuin 7; ADC, adenocarcinoma; SCC, squamous cell carcinoma.